Live Earnings Conference Call: Viking Therapeutics will host a live Q1 2025 earnings call on April 23, 2025 at 4:30PM ET. Follow this link to get details and listen to Viking Therapeutics' Q1 2025 earnings call when it goes live. Get details. Viking Therapeutics (VKTX) News Today $25.48 +1.76 (+7.42%) Closing price 04/22/2025 04:00 PM EasternExtended Trading$26.47 +0.99 (+3.89%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Legal & General Group PlcLegal & General Group Plc lowered its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 9.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,370 shares of the biotechnology coApril 22 at 3:41 AM | marketbeat.comSterling Capital Management LLC Sells 35,290 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Sterling Capital Management LLC lessened its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 87.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,073 shares of the biotechnology company's stock after selApril 21 at 3:41 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Receives $89.75 Consensus Price Target from AnalystsApril 20 at 1:47 AM | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 1.4% - Time to Buy?Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 1.4% - Still a Buy?April 19, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Altium Capital Management LLCAltium Capital Management LLC increased its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 146,000 shares of the biotechnology coApril 19, 2025 | marketbeat.comRaymond James Financial Inc. Acquires Shares of 618,469 Viking Therapeutics, Inc. (NASDAQ:VKTX)Raymond James Financial Inc. bought a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 618,469 shares of the biotechnology company's stock, valued at approximaApril 19, 2025 | marketbeat.comViking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735April 19, 2025 | finance.yahoo.comViking Therapeutics (NASDAQ:VKTX) Shares Down 1.7% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Shares Down 1.7% - What's Next?April 18, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)HC Wainwright reiterated a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research note on Thursday.April 18, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Down - What's Next?Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down - Time to Sell?April 18, 2025 | marketbeat.comOsterweis Capital Management Inc. Boosts Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)Osterweis Capital Management Inc. boosted its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 23.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 155,445 shares of the biotechnology companyApril 18, 2025 | marketbeat.comWasatch Advisors LP Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)Wasatch Advisors LP lowered its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 20.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 180,918 shares of the biotechnology company's stock aftApril 18, 2025 | marketbeat.comJump Financial LLC Buys Shares of 93,372 Viking Therapeutics, Inc. (NASDAQ:VKTX)Jump Financial LLC purchased a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 93,372 shares of the biotechnology company's sApril 18, 2025 | marketbeat.comJPMorgan says Lilly data ‘highly favorable’ for Structure TherapeuticsApril 17, 2025 | markets.businessinsider.comViking Therapeutics slips after Eli Lilly reports orforglipron trial resultsApril 17, 2025 | markets.businessinsider.comViking Therapeutics (NASDAQ:VKTX) Shares Down 0.5% - Should You Sell?Viking Therapeutics (NASDAQ:VKTX) Shares Down 0.5% - Time to Sell?April 17, 2025 | marketbeat.comViking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)April 17, 2025 | seekingalpha.com2 Stocks Down by 25% or More This Year to Buy and HoldApril 17, 2025 | fool.comWells Fargo & Company MN Buys 69,355 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Wells Fargo & Company MN boosted its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 36.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 261,635 shareApril 17, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen research firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, ten haveApril 17, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Down 5.6% - What's Next?Viking Therapeutics (NASDAQ:VKTX) Stock Price Down 5.6% - Here's WhyApril 16, 2025 | marketbeat.comViking Therapeutics Stock Pops But Struggles to Hold GainsVKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in WashingtonApril 16, 2025 | marketbeat.comViking Therapeutics (VKTX) Projected to Post Quarterly Earnings on WednesdayApril 16, 2025 | americanbankingnews.comViking Therapeutics (VKTX) Projected to Post Earnings on WednesdayViking Therapeutics (NASDAQ:VKTX) will be releasing earnings before the market opens on Wednesday, April 23, Financial Modeling Prep reports.April 16, 2025 | marketbeat.comTraders Purchase High Volume of Viking Therapeutics Call Options (NASDAQ:VKTX)April 16, 2025 | americanbankingnews.comViking Therapeutics: Trading The Volatility Of The Weight Loss Drug MarketApril 15, 2025 | seekingalpha.comViking Therapeutics (NASDAQ:VKTX) Shares Up 10.9% - Still a Buy?Viking Therapeutics (NASDAQ:VKTX) Trading 10.9% Higher - Here's What HappenedApril 15, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Up - Still a Buy?Viking Therapeutics (NASDAQ:VKTX) Shares Gap Up - Time to Buy?April 15, 2025 | marketbeat.comDown 71%, Should You Buy the Dip on Viking Therapeutics Stock?April 15, 2025 | fool.comWhy Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday?April 15, 2025 | msn.comStock Traders Buy Large Volume of Call Options on Viking Therapeutics (NASDAQ:VKTX)Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders bought 30,549 call options on the company. This represents an increase of 90% compared to the average daily volume of 16,040 call options.April 15, 2025 | marketbeat.comViking, Structure rally after Pfizer halts obesity drug developmentApril 14, 2025 | markets.businessinsider.comBTIG highlights some reasons to own Viking shares after danuglipron discontinuedApril 14, 2025 | markets.businessinsider.comWhy Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped TodayApril 14, 2025 | fool.comWhat's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?April 14, 2025 | benzinga.comViking Therapeutics shares surge on Pfizer’s drug discontinuationApril 14, 2025 | au.investing.comViking Therapeutics (NASDAQ:VKTX) Shares Down 0.4% - What's Next?Viking Therapeutics (NASDAQ:VKTX) Shares Down 0.4% - Time to Sell?April 12, 2025 | marketbeat.com3 Magnificent Stocks That Could Double or More by 2030April 12, 2025 | fool.comQuinn Opportunity Partners LLC Makes New $3.38 Million Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)Quinn Opportunity Partners LLC purchased a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 83,889 shares of the biotechnology company's stock, valuedApril 12, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 143,854 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Russell Investments Group Ltd. lessened its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 35.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 262,163 shares of the biotecApril 12, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC raised its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,880,713 shares of the biotechnology companApril 12, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Down 7.5% - Here's WhyViking Therapeutics (NASDAQ:VKTX) Shares Down 7.5% - Here's WhyApril 11, 2025 | marketbeat.comLPL Financial LLC Increases Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)LPL Financial LLC increased its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 18.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 96,702 shares of the biotechnology company's stoApril 11, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Stock Price Up 1.8% - Time to Buy?Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 1.8% - Here's What HappenedApril 10, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Fmr LLCFmr LLC grew its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 0.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,715,438 shares of the biotechnology company's stock afterApril 10, 2025 | marketbeat.comWill Viking Therapeutics Be a Top Healthcare Stock in 10 Years?April 10, 2025 | fool.comWill Viking Therapeutics Be a Top Healthcare Stock in 10 Years?April 10, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Trading Down 1.7% - Time to Sell?Viking Therapeutics (NASDAQ:VKTX) Shares Down 1.7% - Here's WhyApril 9, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Coverage Initiated at The Goldman Sachs GroupThe Goldman Sachs Group began coverage on shares of Viking Therapeutics in a research report on Tuesday. They set a "neutral" rating and a $30.00 price objective for the company.April 9, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Hits New 1-Year Low - Here's WhyViking Therapeutics (NASDAQ:VKTX) Sets New 12-Month Low - Here's What HappenedApril 9, 2025 | marketbeat.com Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Media Mentions By Week VKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VKTX News Sentiment▼0.820.76▲Average Medical News Sentiment VKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VKTX Articles This Week▼2616▲VKTX Articles Average Week Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today BridgeBio Pharma News Today Legend Biotech News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VKTX) was last updated on 4/23/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
